SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo, AstraZeneca ink supply pact

07 Sep 2010 Evaluate

Aurobindo Pharma, has signed a deal with the UK-based AstraZeneca to supply a range of generic drugs. Aurobindo will supply 25 solid dosage and sterile products to be sold in 40 emerging markets, excluding India and China. These products will address therapeutic segments such as anti-infective, cardiovascular system and central nervous system. 

The deal is the second such agreement for the Hyderabad-based drug maker in the past two years. A similar one with US giant Pfizer was signed in March last year. Together, the two deals are expected to produce $350-$500-million revenue next year.

crackcrack

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×